GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
January 10, 2025 07:00 ET
|
GH Research PLC
Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of patients in remission at Day 8Primary endpoint...
Online Couples Therapy and Counseling Services Market Report 2024: A $26 Billion Industry by 2028 Driven by Mobile Apps - Long-term Forecast to 2033
January 06, 2025 09:29 ET
|
Research and Markets
Dublin, Jan. 06, 2025 (GLOBE NEWSWIRE) -- The "Online Couples Therapy and Counseling Services Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The online couples...
Magstim Horizon Inspire Transcranial Magnetic Stimulation Device Approved by UKCA for NHS & Private UK Clinics
December 05, 2024 04:02 ET
|
Magstim EGI
UKCA Approves Magstim Horizon Inspire TMS for NHS & Private UK Clinics. UK Made System for Patient Treatment of MDD, OCD and Decreasing Anxiety.
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 14, 2024 07:00 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 clinical trial to evaluate proprietary aerosol delivery...
FDA Clears Magstim Horizon INSPIRE Transcranial Magnetic Stimulation System to treat Depression, OCD, Anxious Depression
November 12, 2024 08:11 ET
|
Magstim EGI
FDA clears Magstim INSPIRE Transcranial Magnetic Stimulation TMS system to treat patients with Depression, OCD, Anxious Depression
Two in Five Americans Say Their Mood Worsens in Winter; 29% Say “Falling Back” Hurts Their Mental Health
October 30, 2024 10:00 ET
|
American Psychiatric Association
Washington, D.C., Oct. 30, 2024 (GLOBE NEWSWIRE) -- As the nation “falls back” to standard time, Americans are twice as likely to say their mood declines in the winter (41%) as they are to say it...
Nexstim Receives NBS System 5 Order from European Customer
October 02, 2024 02:00 ET
|
Nexstim Oyj
Press release, Helsinki, 2 October 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from European Customer Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS...
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
September 03, 2024 07:05 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label...
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
September 03, 2024 07:00 ET
|
GH Research PLC
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
Anxiety Disorders and Depression Treatment Global Market Report 2024-2032: Sturdy Medication Pipelines to Support Development, Economic Cost of Mental Illnesses to Drive Demand
August 30, 2024 04:15 ET
|
Research and Markets
Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Anxiety Disorders and Depression Treatment Global Market Report, Forecast by Product, Indication, Country and Company Analysis 2024-2032" report has...